North America and the UK were the fastest-growing drug markets in 1994, expanding by 8% to $52.9 billion and $5.6 billion respectively, according to new figures published by IMS International. This compares with selected world growth of 5% to $122.3 billion. The growth has been achieved despite public and private sector efforts to control health care costs in many countries across the globe.
The fastest-growing therapeutic sectors in the USA were central nervous system drugs (17%), cardiovascular drugs (16%) and alimentary and metabolism drugs (16%). Respiratory drugs also showed an 11% increase.
Overall, growth in the top seven markets in Europe was $46.9 billion, up 3% compared to 1993. The biggest growing category was cardiovascular drugs (up 22%), followed by alimentary/metabolism (18%), CNS (11%) and anti-infectives and respiratory agents (10%).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze